OCGN - NASDAQ
Ocugen, Inc.
$1.34
-5.1%Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
At a Glance
Live SnapshotOcugen, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Ocugen, Inc. Cash Flow Statement
OCGN • NASDAQ
| Ocugen, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||
-67.8M | -54.1M | -63.1M | -86.8M | -58.4M | -21.8M | -20.2M | -8.6M | -26.4M | -16.2M | -32M | -22.8M | -25.7M | -16.9M | |
2.4M | 2M | 704K | 480K | 229K | 102.1K | 60.6K | 450K | 1.5M | 1.7M | 1.6M | 726K | 566K | 638K | |
0.0 | 0.0 | 0.0 | 0.0 | -52K | 0.0 | 3.2M | -17.1M | 1.5M | -14.2M | 321K | 60K | 80K | 2.4M | |
7.7M | 7.4M | 9.2M | 10.5M | 7M | 660K | 884.1K | 1.6M | 1.6M | 1.5M | 1.2M | 547K | 158K | 14K | |
1.3M | -1.1M | 4.3M | 6.5M | 799K | 7.6M | 2.3M | 10.7M | -543K | -533K | -322K | 672K | 8.4M | 1.6M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (105K) | (197K) | (257K) | (79K) | (2K) | (0.0) | (0.0) | |
-523K | 3.7M | -13.2M | 9.2M | 2.5M | -1.2M | -3.1M | -2.8M | -706K | 2M | -851K | 2.4M | 1.3M | 48K | |
-57M | -42.1M | -62.1M | -60.1M | -47.9M | -14.7M | -16.9M | -15.8M | -23M | -25.7M | -30M | -18.4M | -15.3M | -12.2M | |
INVESTING ACTIVITIES | ||||||||||||||
-185K | -3.4M | -10.5M | -4.5M | -939K | -306.8K | -29.4K | -2M | -276K | -320K | -1.9M | -3.3M | -604K | -79K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -2.3M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | -3.9M | -13.3M | (0.0) | (0.0) | (0.0) | (0.0) | -8M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 17.5M | 0.0 | 0.0 | 0.0 | 0.0 | 900K | 7.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-126K | 0.0 | 0.0 | 761K | -877K | 0.0 | -273.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 50K | 0.0 | |
-311K | -3.4M | (3.1M) | -17M | -1.8M | -306.8K | -2.4M | -1.1M | -1.2M | -320K | -1.9M | -3.3M | -554K | -79K | |
FINANCING ACTIVITIES | ||||||||||||||
18.3M | 38.6M | 20.8M | 59.6M | 129.2M | 37.8M | 1.1M | 25.5M | 0.0 | 27.6M | 4.7M | 60.5M | 0.0 | 0.0 | |
-1M | 30M | 500K | 500K | -10K | -4.7M | 1.4M | -178K | -583K | -583K | -406K | 1.8M | 0.0 | 6M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -48K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | -3.7M | -68K | -592K | -8.5M | -1.5M | 0.0 | 3K | 6K | 2K | 39K | -1.5M | -407K | 0.0 | |
17.3M | 64.9M | 20.9M | 59.5M | 120.7M | 31.6M | 25.1M | 25.4M | -577K | 27M | 4.4M | 71.1M | 9.9M | 26.7M | |
CASH FLOW SUMMARY | ||||||||||||||
13K | 28K | -5K | 25K | 0.0 | 0.0 | 0.0 | 451.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-39.9M | 19.4M | -38.1M | -17.5M | 70.9M | 16.6M | 5.8M | 8.5M | -24.8M | 993K | -27.6M | 49.3M | -6M | 14.4M | |
58.8M | 39.5M | 77.6M | 95.1M | 24.2M | 7.6M | 1.8M | 7.2M | 31.9M | 30.9M | 58.5M | 8.7M | 14.7M | 339K | |
18.9M | 58.8M | 39.5M | 77.6M | 95.1M | 24.2M | 7.6M | 15.7M | 7.1M | 31.9M | 30.9M | 58.1M | 8.7M | 14.7M | |
-57.1M | -45.5M | -72.5M | -64.5M | -48.9M | -15M | -16.9M | -17.8M | -23.3M | -26.1M | -32M | -21.7M | -15.9M | -12.3M |
SEC Filings
OCGN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | May 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 08, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 08, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 24, 2026 | 2026 |
Related Guides
Continue your OCGN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.